drugset
drugset / Trial / NCT06614816

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years

NCT06614816 ↗

Phase 3 Completed 1200 enrolled Southeast University, China Jiangsu CDC · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study

Timeline

Start
2019-02-10
Primary completion
2021-07-15
Completion
2022-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Oka strain varicella attenuated live vaccine Vaccine — Subcutaneous

Indications

chickenpox